New research has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC). 

The study, published in Genome Medicine and funded by the charity Breast Cancer Now and others, pinpoints important genes that could be targeted by new drugs. 

TNBC accounts for roughly 10-15% of all breast cancers and most commonly affects Black women below the age of 40 who have inherited the BRCA2 gene. 

Many patients receive neoadjuvant therapy, but around 45% of patients are left with residual cancer cells in the breast (drug-tolerant persister cells) presenting a much higher risk of recurrence. 

For this study, the Institute of Cancer Research (ICR) team, co-led by Dr Rachael Natrajan and Dr Syed Haider in the Breast Cancer Now Toby Robins Research Centre, within the Division of Breast Cancer Research, used single-cell sequencing to analyse more than 129,000 individual TNBC cells derived from laboratory models from tumours that had residual disease. 

A new vulnerability to exploit

The analysis revealed that residual tumours often contain different types of cancer cells that are particularly resistant to treatment. One group is adapted to survive in low‑oxygen (hypoxic) conditions, while the other shows a heightened activation of immune‑related signalling pathways. 

The hypoxia-associated cells were found to be especially aggressive, carrying molecular features linked to long-term survival, treatment resistance and a greater ability to spread to other parts of the body.When exposed to chemotherapy, they can manipulate pathways to rapidly switch on survival tactics. 

The team also identified several key regulators controlling these drug-tolerant persister cells, including a gene called KDM5B, which helps regulate gene expression programmes of drug tolerant cells and is activated under low oxygen conditions. 

Dr Natrajan, Leader of the Functional Genomics Group at the ICR, said: “When we blocked KDM5B in our lab work, we were able to delay the emergence of these resistant cells after chemotherapy. While this is still early-stage research, it suggests that targeting this pathway could one day help prevent tumours from returning. With this new vulnerability to exploit, we can potentially stop these cells from taking hold after treatment and improve long-term outcomes for TNBC patients.”